drugset / Trial / NCT02935790
Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab
Phase 1
Completed
1 enrolled
Celgene Corporation
ApoCell, Inc. · collabCelerion · collabNYU Langone Health · collabSyneos Health · collab
NaSingle-groupOpen-labelTreatment
Summary
Determine the safety, tolerability, dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of ACY-241 in combination with ipilimumab and nivolumab in patients with unresectable Stage III/Stage IV melanoma.
Timeline
- Start
- 2016-09-30
- Primary completion
- 2017-04-07
- Completion
- 2017-04-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Citarinostat | Small molecule | — | — |
| Background | Ipilimumab | Monoclonal antibody | 1 mg/kg | — |
| Background | Nivolumab | Monoclonal antibody | 240 mg | — |